Changes to conventional cohort eligibility criteria

by H Ali | May 8, 2025 | News

As part of the 14th Substantial Amendment for the study, there have been some changes to the eligibility criteria for patients on conventional treatments. The implementation date for Substantial Amendment 14 is 08/05/2025; these changes will affect any patients...

Amendment 14

by H Ali | Apr 8, 2025 | Amendments

BADBIR Participants Using the Patient Portal Your data Participant FAQs Patient Newsletters Clinicians Eligibility Study information Conducting BADBIR remotely Associate Principal Investigator Scheme Centre Report Average daily dose Participating centres Steering...

Age and biologic survival in patients with ​moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

by H Ali | Jan 10, 2025 | Publications

BADBIR Participants Using the Patient Portal Your data Participant FAQs Patient Newsletters Clinicians Eligibility Study information Conducting BADBIR remotely Associate Principal Investigator Scheme Centre Report Average daily dose Participating centres Steering...

Taltz (ixekizumab) recruitment has restarted

by H Ali | Dec 12, 2024 | News

BADBIR Participants Using the Patient Portal Your data Participant FAQs Patient Newsletters Clinicians Eligibility Study information Conducting BADBIR remotely Associate Principal Investigator Scheme Centre Report Average daily dose Participating centres Steering...

BADBIR Annual Update 2024

by H Ali | Nov 28, 2024 | Clinician Newsletters, Newsletters

Welcome to the 2024 BADBIR Update. Led by the British Association of Dermatologists and co-ordinated at the University of Manchester, since 2007 BADBIR has grown to be a leading source of real-world data for researching psoriasis therapies. While we prepare this...